Centene (NYSE:CNC) Corporation CNC reported second-quarter 2021 adjusted earnings per share of $1.25, which missed the Zacks Consensus Estimate by 11.3%. However, the bottom line improved 47.9% year over year attributable to higher revenues.
In the second quarter, total revenues improved 12% year over year to $31 billion, led by the recent PANTHERx buyout, membership growth in the Medicare business and the continuing suspension of Medicaid eligibility redeterminations. The top line also outpaced the consensus mark by 3%.
Centene Corporation Price, Consensus and EPS Surprise
Centene Corporation price-consensus-eps-surprise-chart | Centene Corporation Quote
Quarterly Operational Update
As of Jun 30, 2021, managed care membership totaled 25.4 million, which climbed 3% year over year.
In the reported quarter, Health Benefits Ratio (HBR) came in at 88.3%, which expanded 620 basis points (bps) year over year. The reason can primarily be attributed to reduced medical utilization trends stemming from the COVID-19 pandemic and higher utilization in the Marketplace business along with an unfavourable 2020 risk adjustment that took place in 2021.
Adjusted selling, general and administrative (SG&A) expense ratio was 7.7% in the quarter, down 80 bps year over year. The decline could be attributed to lower short-term variable compensation costs, leveraging of costs over higher revenues from increased Medicaid enrolment and a recent few buyouts.
Financial Update (as of Jun 30, 2021)
Total assets were up 4.1% from the 2020-end figure to $71.5 billion.
Centene’s long-term debt was $16.5 billion, which dipped 0.9% from the figure at 2020 end.
In the first six months of 2021, net cash provided by operating activities totaled $1.7 billion, down 50.3% year over year.
2021 Guidance Updated
Concurrent with second-quarter results, the company revised its full-year outlook.
For the current year, management anticipates revenues in the $123.3-$125.3 billion range, up from the previous band of $120.1-$122.1 billion.
In 2021, the company’s adjusted EPS is still expected to be $5.05-$5.35.
This year, HBR is forecast between 87.5% and 88.1% compared with the prior range of 87.1-87.7%.
The guidance for adjusted SG&A expense ratio now stands in the range of 8-8.4%.
Zacks Rank
Centene currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Among other players from the medical space that have reported second-quarter earnings so far, the bottom-line results of UnitedHealth Group Incorporated (NYSE:UNH) UNH, Tenet Healthcare Corporation (NYSE:THC) THC and HCA Healthcare (NYSE:HCA), Inc. HCA beat estimates.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Tenet Healthcare Corporation (THC): Free Stock Analysis Report
HCA Healthcare, Inc. (HCA): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research